ArticleInvestigational new drugs2021

A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer.

Hyehyun Jeong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.